Couverture de Minor Tweak, Major Impact

Minor Tweak, Major Impact

Minor Tweak, Major Impact

De : Minor Tweak Major Impact
Écouter gratuitement

À propos de ce contenu audio

 A short-form science podcast Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Minor Tweak, Major Impact Podcast Introduction

      Minor Tweak, Major Impact Podcast Introduction
      Mar 13 2019
      Minor Tweak, Major Impact is a short form podcast about scientific research methods. The show looks into a series of stories related to following protocols and how a minor tweak can produce major results, major impact.
      Afficher plus Afficher moins
      Moins d'une minute
    • Episode 01: Luke Schwerdtfeger, Colorado State University

      Episode 01: Luke Schwerdtfeger, Colorado State University
      Mar 13 2019
      Luke Schwerdtfeger graduated from Colorado State University with a Bachelor's Degree in Biological Sciences, prior to joining the same universities PhD program in the Department of Biomedical Sciences. Luke’s doctoral work, for which he is advised by Dr. Stuart Tobet, focuses on understanding the nervous system of the mammalian intestine and how it functions in response to pathogen invasion.
      Afficher plus Afficher moins
      12 min
    • Episode 02: Dr. Glenn Begley, CEO of BioCurate

      Episode 02: Dr. Glenn Begley, CEO of BioCurate
      Mar 25 2019
      Dr. Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development. He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2017) and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016). From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen’s 5 research sites. There he highlighted the issue of research integrity and scientific reproducibility. Since then he has made multiple presentations on the subject of scientific integrity including to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, the British Broadcasting Company, Australian National Health and Medical Research Council, and numerous Universities, Research Institutes and companies. Before Amgen he had over 20 years of clinical experience in medical oncology and hematology. His personal research focused on regulation of hematopoietic cells and translational clinical trials. His early studies, in Prof Donald Metcalf’s department first described human G-CSF, and in later clinical studies, performed in Professor Richard Fox’s Department at the Royal Melbourne Hospital, the group first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery, a finding that revolutionized bone-marrow transplantation. His honors include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, and in 2014 to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital and to the Australian Academy of Health and Medical Sciences.
      Afficher plus Afficher moins
      18 min
    Aucun commentaire pour le moment